Abstract Pregnancy and postpartum are periods of high susceptibility to major depression (MD) and other mood disorders. The peripartum period is also a time of considerable changes in the levels of hormones, including cortisol, thyroid-stimulating hormone (TSH), prolactin, gonadotropins, and gonadal steroids. To investigate the relationship between mood and hormonal changes during and after pregnancy, we reviewed published reports of hormonal measures during this time frame, searched via PubMed and Web of Science. Studies were included if women in the antepartum or postpartum periods were clinically diagnosed with MD, and if there were repeated measures of cortisol, TSH, or prolactin. For these three hormones, the numbers of human studies that met these criteria were 15, 7, and 3, respectively. Convergent findings suggest that morning cortisol is reduced in pregnant and postpartum women with MD. Evidence did not support changes in TSH as a marker of MD during the peripartum period, and evidence for changes in prolactin in peripartum MD was equivocal. Aside from reduced morning cortisol in peripartum women with MD, definitive evidence for an association between specific hormonal fluctuations and mood disorders in the peripartum period remains elusive.
Introduction
Major depression (MD) is among the most predominant mental health disorders in the USA. Women are twice as likely as men to experience MD during their lifetimes, and lifetime prevalence of MD in women is 6-17% (Kessler 2003) . In one study, almost two thirds of pregnant women met Diagnostic and Statistical Manual (DSM)-IV (American Psychiatric Association 2013) criteria for a major depressive episode (MDE) within the past year when interviewed by a clinician, yet these women were unaware of their diagnosis and had not received mental health treatment (Ko et al. 2012 ). Marcus similarly reported that only 20% of women who met criteria for MD during pregnancy were engaging in treatment (Marcus 2009 ). Depression in the 12 months postpartum occurs at a rate of 9-22% (Vesga-Lopez et al. 2008; Gavin et al. 2005; Wisner et al. 2013) . If untreated, peripartum MD is associated with detrimental outcomes (Brockington et al. 2017) ; for mothers, these include increased risk of smoking, substance abuse, poor nutrition, marital conflict, and subsequent recurrence of depression (Le Strat et al. 2011; Stewart and Vigod 2016) . For offspring, detrimental outcomes include preterm birth, poor fetal growth, low birth weight, dysregulated attention and arousal (which can progress to attention deficit hyperactivity disorder), impaired adaptive functioning and anxiety, decreased cognitive ability, and elevated stress reactivity in the teenage years (Muzik et al. 2009; Grote et al. 2010; Bernard-Bonnin 2009; Ciesielski et al. 2015; Halligan et al. 2007; Barry et al. 2015) . Treatment of maternal depression leads to a decrease in child psychopathology (Weissman et al. 2006) . Clearly, the prevalence of peripartum MD, its low rates of recognition and treatment, and its lasting deleterious consequences for mothers and children make understanding the pathophysiology and treatment of this condition a high public health priority.
Aim of current review
In addition to the susceptibility of mood changes, the peripartum period is characterized by rapid and significant changes in hormones, including cortisol, thyroid-stimulating hormone (TSH), prolactin, gonadotropins, and gonadal steroids (Bloch et al. 2003; Parry et al. 2003 Parry et al. , 2006 . To understand this temporal association and a potential causal link between depression and changes in non-gonadal hormones during the peripartum period, we systematically reviewed published findings of cortisol, TSH, and prolactin in women with MD. Our goal was to determine if any of these three hormones had confirmed correlations-positive or negative-in women with peripartum MD.
Methods Search
Because structured clinical interviews have greater sensitivity to accurate diagnosis compared with self-reported measures (Parcells 2010) , we focused on MD diagnosed by clinical interview, most commonly by the Structured Clinical Inventory for DSM Disorders-IV (SCID-IV). Studies using self-report screening measures as the sole clinical instrument were not included in this review nor were studies focused on postpartum Bblues^or subsyndromal depressive symptoms. Articles were identified via PubMed or Web of Science using specific search criteria, e.g., Bdepression,^Bpregnancy,B postpartum,^and Bcortisol^for the first section. Additional citations were identified as BSimilar Articles^in PubMed. This procedure is further explained as a flow chart in Fig. 1 .
Inclusion and exclusion criteria
Articles had to meet the following criteria to be included in this review: (1) publication date between 1996 and August 1, 2016; (2) written in English; (3) studies in humans; and (4) diagnosis of MD made by a clinician. In addition, multiple measurements of cortisol were required to account for diurnal variation, or conversely, urine collection over time; for TSH and prolactin, one plasma sample was required. Articles were excluded if they were case reports or review articles.
Data extraction and quality of studies
Data extracted from each study included author, year, timing of sample, source of sample and method of sample measurement (cortisol only), method of MD diagnosis, use of other depression scales, and a brief description of reported outcomes. The quality of each study was determined using the Newcastle-Ottawa Quality Assessment Scale. A NewcastleOttawa Score (NOS) of 9 indicates the highest quality and therefore lowest risk of bias, whereas score of 3 or lower confers a high risk of bias; a score of 4-6 indicates a moderate risk of bias (Deeks et al. 2003) . Additionally, limitation(s) are reported in the second to last column. In the studies where no limitations were found in terms of inclusion in this review, BN/ a^is listed in the limitations column, meaning Bnot applicable.Ĉ ortisol in antepartum and postpartum major depression Cortisol, the steroid hormone upregulated by hypothalamicpituitary-adrenal (HPA) axis signaling in the setting of stress, is elevated in depressed patients (Carroll et al. 1976; Linkowski et al. 1985) . Cortisol secretion follows a circadian rhythm, rising in early morning to a mid-morning peak, then declining in the evening before sleep onset. Altered sleep onset, offset, and duration change cortisol production (Balbo et al. 2010) . As shown in Figs. 1, 15 studies were identified that included women in the peripartum period who were diagnosed with MD by a clinician and had repeated cortisol measures to account for circadian rhythm variation (Table 1) . These studies varied in cohort characteristics, timing, frequency, and source (saliva, serum, urine) of cortisol sampling. They have been grouped by pregnancy status-i.e., pregnant vs. postpartum-followed by interventional studies. Field et al. (2006 Field et al. ( , 2008 published studies on a cohort of 430 pregnant women recruited from a university hospital. During the second trimester (approx. 20 weeks gestation), 172 (40%) of these women were determined to have either MD or dysthymia by structured clinical interview. Morning urinary cortisol was collected at this time point and again during the third trimester (approx. 32 weeks gestation), during scheduled fetal ultrasound appointments. Spot urinary cortisol was higher in depressed women compared to pregnant healthy control subject (HCS) during the second trimester. Additionally, second trimester depression was predictive of third trimester depression, anxiety, and sleep disturbance. During third trimester sampling, however, cortisol was not higher in depressed women. Interestingly, depressed women had shorter gestations by approximately 1.5 weeks compared to HCS, and the newborns from depressed women had lower birth weights. In a larger study by these investigators (Field et al. 2010) , 911 subjects were recruited from university hospital prenatal clinics and subsequently followed from the second trimester of pregnancy onwards; 181 (19.9%) were diagnosed with MD, 77 with anxiety, and 308 (33.8%) with comorbid MD and anxiety. Morning urinary cortisol was collected at approx. 20 and 32 weeks gestation and 2 days postpartum. Contrary to their prior study (Field et al. 2006) , no difference in cortisol was detected between women with vs. without a diagnosis of MD or anxiety. The high rate of depression in this larger study (54%) and their earlier one suggest that low diagnostic specificity may have contributed to the failure to reproduce findings across studies (Field et al. 2010) .
Among 182 women in their second trimester of pregnancy, Evans et al. (2008) identified 16 (8.8%) with MD, 34 with anxiety, and 9 (4.9%) with comorbid MD and anxiety. At 36 weeks gestation, salivary cortisol was collected at three time points as the subjects completed computer-based tasks: between 1030 and 1130, then 30 and 90 min later. The computer-based tasks included a Stroop color-word matching task, a mental arithmetic task, or a controlled breathing task. Women with comorbid MD and anxiety had higher cortisol levels at multiple time points. However, cortisol levels did not differ between women diagnosed with MD or anxiety alone vs. pregnant HCS.
Parcells (2010) studied depression, anxiety, and stress in 59 pregnant women, but only 28 research participants completed both time points. Salivary cortisol levels were sampled at 26-28 and 32-34 weeks gestation, between 1000 and 1130. Rates of MD by clinical interview were 32.1 and 23.1% during the second and third trimesters, respectively. No association between cortisol and MD was identified. The reduced rate of depression in the third vs. second trimester suggests differences in these cohort characteristics, which may reflect attrition of the most severely depressed women, or it may represent over-identification of depressed subjects since the rate of 32.1% is higher than the general population.
Rouse and Goodman (2014) compared urinary cortisol (from waking until noon) of pregnant women diagnosed with MD (n = 23) vs. pregnant HCS (n = 54); samples were collected monthly throughout pregnancy. Cortisol levels increased over the course of pregnancy, but the levels did not differ across groups.
O 'Connor et al. (2014) recruited over 100 pregnant women in their first trimester; 23 were diagnosed with MD. Salivary cortisol was measured five times daily-at awakening, and 45 min, 2.5 h, 8 h, and 12 h later-during the second (approx. 21 weeks) and third trimesters (approx. 34 weeks). Compared to pregnant HCS, women with MD had significantly reduced levels of morning cortisol, followed by higher cortisol levels later in the day.
The first study focused on the postpartum period;, Harris et al. (1996) examined salivary cortisol twice a day (0800 and 2200) from 120 women, from 2 weeks antepartum to 35 days postpartum. Seven of these women developed MD by 6 weeks postpartum. Compared with non-depressed women, the depressed women had lower evening cortisol levels in the immediate postpartum period but did not differ in morning cortisol levels.
In a pilot study, Parry et al. (2003) investigated plasma cortisol in both pregnant women (3 with MD, 2 HCS) and postpartum women (13 with MD, 2 HCS), via frequent sampling-every 30 min from 1800 until the following morning at 1100. Repeated, frequent cortisol measures allow for cosine analysis to determine (1) amplitude, or half the value of a cosine function; (2) mesor, or midpoint of a cosine function; and (3) acrophase, or peak value of a cosine function. During pregnancy, cortisol amplitude was lower in depressed vs. nondepressed women. Postpartum, cortisol amplitude was higher in depressed vs. non-depressed women. In both ante-and postpartum, the cortisol acrophase was earlier in depressed vs. non-depressed women. The use of repeated, frequent sampling in this study identified (1) the importance of time of day for cortisol measurement and 2) that absolute cortisol levels change during pregnancy and postpartum. Taylor et al. (2009) Deeks et al. (2003) samples were collected at awakening, and 30 min, 3 h, and 12 h later. Compared with HCS, non-depressed, postpartum women showed a similar cortisol secretion pattern, with a rise between the first and second salivary collections, followed by a decline throughout the rest of the day. Cortisol from depressed, postpartum women, however, was stable between the first and second salivary collections, followed by a decline similar to the other subjects. The authors commented that this lack of rise in morning cortisol had been similarly demonstrated in women with posttraumatic stress disorder (Wessa et al. 2006 ).
In women who were 6 months postpartum, de Rezende et al. (2016) obtained salivary cortisol at awakening and 30 min, 3 h, and 12 h later. The study included 37 depressed, postpartum women; 42 euthymic, postpartum women; and 25 non-perinatal HCS. Both groups of postpartum women demonstrated attenuation of morning cortisol awakening response (CAR) compared to HCS, but it was more pronounced in the depressed, postpartum women. Additionally, this cohort manifested significantly lower cortisol at awakening, 30 min later and 3 h later compared to non-postpartum HCS. The EPDS scores of the depressed, postpartum subjects were negatively correlated with the CAR.
Four interventional studies met our review criteria. Okun et al. (2011) studied 56 pregnant, euthymic women at Bhigh risk^(HR) for MD based on a past history of MD, including postpartum depression (PPD), were randomized to receive nortriptyline, sertraline, or placebo. Serum cortisol samples and self-reported sleep quality were collected biweekly during the first 17 weeks postpartum. Cortisol initially declined but then returned to gestational levels by 11-17 weeks postpartum. Twelve (21.4%) HR women had a recurrence of MD during this period, which was predicted by subjective measure of poor sleep quality but not by cortisol levels.
In a study by Urizar and Muñoz (2011) , pregnant women identified as HR based on a past MDE and current depressive symptoms were randomized to two groups: cognitivebehavioral therapy (CBT) for stress management (n = 24) vs. usual care (n = 33) during their second trimester. Salivary cortisol levels were obtained 45 min after awakening and at 2000 at three time points: during pregnancy and 6 and 18 months postpartum. Samples were compared to pregnant HCS (n = 29). No differences in cortisol were detected during pregnancy and 6 months postpartum among the three cohorts. At 18 months postpartum, lower cortisol levels were detected in the group of mothers at HR for depression who attended more CBT classes, by interindividual comparison.
In another CBT-interventional study, Richter et al. (2012) used the Munich-Composite International Diagnostic Interview (CIDI) to identify subclinical depression in women during their first trimester, who then were randomized to receive CBT (n = 21) vs. no intervention (n = 40). Salivary cortisol was obtained five times during the course of a day-awakening, 30 min later, 1100, 1700, and 2200-at three different dates: second trimester baseline (approx. 23 weeks gestation), third trimester post intervention (approx. 34 weeks gestation), and 3 months postpartum. In the CBT group, morning cortisol (30 min after awakening) was reduced vs. no intervention after four to eight sessions of CBT in the antenatal period and 3 months postpartum.
In a fourth interventional study, Field et al. (2013) randomized pregnant women diagnosed with MD to 12 weekly sessions of yoga (n = 40) vs. support group (n = 39). Salivary cortisol samples and depression self-rating were obtained mid-morning, before and after the first and last session of yoga or support group (exact time not reported). Both treatments reduced depression, anxiety, and anger. Salivary cortisol was increased later in pregnancy, as expected, but was significantly reduced in samples collected immediately after vs. before the intervention.
In summary, the relationship of peripartum MD and cortisol has been studied using a range of different methodologies, with different diagnostic instruments, source, timing, and frequency of cortisol sampling, as well as with interventions. The absolute level of cortisol rises over the course of pregnancy (Bloch et al. 2003; Parry et al. 2003; Field et al. 2010; Rouse and Goodman 2014) . Convergent studies reported reduced serum or salivary CAR in pregnant women with MD, which normalized later in the day (O'Connor et al. 2014; Parry et al. 2003) ; such findings were not detected with urinary cortisol (Field et al. 2010; Rouse and Goodman 2014) . Evans et al. (2008) determined that salivary cortisol was elevated in women with comorbid MD and anxiety but not in MD alone, which was consistent with subsequent studies by Parcells (2010; salivary) and Field et al. (2008; urinary) . Only one study, which included diagnoses of MD as well as dysthymia in their subjects, determined that urinary cortisol was elevated in depressed women vs. HCS in the second but not the third trimester (Field et al. 2006 ). Findings among three interventional studies during pregnancy (Field et al. 2013; Richter et al. 2012; Urizar and Muñoz 2011) suggest that CBT, stress management, or yoga may all reduce cortisol levels in peripartum MD, though methodological differences preclude direct comparison across studies. The one interventional study comparing medications-two different antidepressants-to placebo in pregnant women at HR for MD did not show a connection between cortisol levels and a diagnosis of MD (Okun et al. 2011) .
In postpartum, depressed women, divergent findings were reported. Parry et al. (2003) reported elevated serum cortisol in a small pilot study, which included different time points during the postpartum period. In contrast, Harris et al. (1996) reported lower evening salivary cortisol at 1 month postpartum. Taylor et al. (2009) reported no rise in morning salivary cortisol in depressed women at 2 months postpartum. Similarly, de Rezende et al. (2016) observed an attenuated CAR at 6 months postpartum in both depressed and healthy controls compared to non-peripartum HCS, but it was more pronounced in the depressed women.
As described in Table 1 , the studies during pregnancy with the lowest risk of bias as determined by NOS found either no correlation between MD and cortisol (Okun et al. 2011; Rouse and Goodman 2014) or a reduced CAR in women with MD (O'Connor et al. 2014 ). Both of the postpartum studies with the lowest risk of bias according to the NOS reported an attenuated CAR in women with MD (Taylor et al. 2009; de Rezende et al. 2016) . Thus, the studies reviewed here suggest a complex pattern, in which cortisol rises across pregnancy, and compared to euthymic women, it is reduced in morning samples from patients with both antepartum MD or PPD diagnosed at 2 to 6 months postpartum.
TSH in antepartum and postpartum major depression TSH, a neuroendocrine hormone influenced by sleep and circadian rhythmicity and exercise, is characterized by low daytime levels followed by a rapid increase and peak near the time of sleep onset (Leproult et al. 1997) . TSH increases with sleep deprivation (Sack et al. 1988) and is modulated by light exposure (Kripke et al. 2010) . During exercise, TSH rises and remains elevated, and this effect is more pronounced with evening exercise (Scheen et al. 1998) . Leproult et al. (2001) determined that TSH is further impacted by postural changes, sleep-wake transition, and social stimulation, all of which fluctuate in the peripartum period due to changes in body habitus and infant care. TSH-and subsequently 3,5,3-triiodothyronine (T3) and thyroxine (T4)-rises during the physiologic hypervolemic state of pregnancy to optimize fetal development (Soldin et al. 2004) . Postpartum, some women experience thyroiditis due to production of thyroid antibodies (Lazarus et al. 1996) , manifesting a transient hyperthyroidism followed by transient hypothyroidism within the first 6 months postpartum; these thyroid changes, however, are only sometimes accompanied by depressive symptomatology (Lazarus et al. 2002) . In clinically normal individuals, TSH declines to prepregnancy levels in the early postpartum period (Soldin et al. 2004) . The focus of this review is confined to changes in TSH (and not T3, T4, or thyroid antibodies) in relationship to peripartum MD (Table 2) , which included seven studies. Abou-Saleh et al. (1998) obtained blood samples from 34 women at 7 days postpartum, between 0900 and 1000. By 8 weeks postpartum, four women had developed MD based on the Present State Examination (PSE). No difference in TSH was detected in the 4 depressed vs. 30 non-depressed women.
In a study by Kent et al. (1999) , among 748 Australian women at 6 months postpartum, 44 (5.9%) had elevated TSH, whereas 25 (3.3%) had reduced TSH, compared to 670 women with normal TSH. By CIDI interview (DSM-III-R criteria), 76 (9.4%) women had MD; no association was detected between TSH levels and MD. Kuijpens et al. (2001) recruited 310 women from routine prenatal checks. At 12 and 32 weeks gestation and at 4, 12, 20, 28, and 36 weeks postpartum, blood samples were collected at home visits. Research Diagnostic Criteria (RDC) diagnosed major and minor depression in 158 women (54.3%) throughout the course of the study; 117 women (40.1%) were diagnosed postpartum. No association between thyroid dysfunction and MD was identified.
From a community hospital, 641 women were recruited by Lucas et al. (2001) , between 36 weeks gestation and 4 days postpartum. Blood samples for TSH were gathered at 1, 6, 9, and 12 months postpartum. MD was diagnosed by DSM-III-R criteria in 11 women, none of whom had abnormal TSH levels; in contrast, 56 (11%) of the non-depressed women had abnormal (elevated or reduced) TSH levels. Oretti et al. (2003) studied 115 thyroid antibody-positive, pregnant women vs. 123 antibody-negative, pregnant women recruited at approximately 16 weeks of pregnancy. The women were assessed for MD by RDC at 8, 12, 20, and 28 weeks postpartum, with concurrent blood sampling for TSH. No association was detected between thyroid dysfunction-either positive thyroid antibody status or altered TSH-and MD. Plaza et al. (2010) diagnosed 104 women with MD within the first 6 months postpartum. Of these, six women (6%) had hyperthyroidism (low TSH), and one woman (1%) had hypothyroidism (elevated TSH). The authors concluded that there was no relationship between alterations in TSH and MD. Parry et al. (2003) examined plasma TSH in both pregnant women (3 with MD, 2 HCS) and postpartum women (13 with MD, 2 HCS), in the protocol described above for cortisol measurements. During pregnancy, TSH acrophase occurred later in depressed vs. non-depressed women; postpartum, TSH acrophase occurred earlier in depressed vs. nondepressed women. TSH amplitude was lower in depressed vs. non-depressed women both during pregnancy and postpartum.
The studies included in this review were designed to determine if TSH is associated with MD in the peripartum period. The one study that identified TSH reductions and shifted acrophase (Parry et al. 2003) utilized frequent, repeated sampling in a pilot study. In the two studies deemed to have a low risk of bias by the NOS, there was no association between thyroid dysfunction and peripartum MD (Kent et al. 1999; Oretti et al. 2003) . Conceivably, abnormal signaling of the hypothalamic-pituitary-thyroid axis or thyroid antibodies in peripartum MD might occur in other thyroid hormones and/ or thyroid antibodies that were not the focus of this review. Nonetheless, current evidence is insufficient to link abnormal TSH levels with peripartum MD.
Prolactin in antepartum and postpartum major depression
Prolactin initiates and maintains lactation, and while it is not circadian-dependent (like cortisol and TSH), it is dependent Deeks et al. (2003) on sleep (Linkowski et al. 1998) . Prolactin increases 20-50 times in healthy pregnancy compared with nulliparity (Moult and Besser, 1981) , and in non-lactating women, levels normalize within 3 weeks of parturition (Hendrick et al. 1998) . Estrogen stimulates prolactin secretion (Marshall et al. 1988) , and similar to prolactin, estrogen rapidly declines after parturition (Liu et al. 1983) . In breastfeeding women, the level of prolactin remains elevated after birth and declines gradually over the course of several months (Liu et al. 1983) . Given these sizable peripartum changes, prolactin has been investigated for its possible role in mood changes, particularly in relation to breastfeeding (Alder and Cox 1983; Kuevi et al. 1983; Harris et al. 1989; O'Hara et al. 1991) . We found three studies that included research subjects with a clinical diagnosis of MD (Table 3 ). Using the protocol described above for TSH measurements, Abou-Saleh et al. (1998) also measured plasma prolactin in 34 postpartum women between 0900 and 1000, 7 days after parturition. Eight weeks postpartum, 4 of 34 women were diagnosed with MD. Day 7 prolactin was significantly lower in women with MD vs. women who did not develop MD. Postpartum women who had previously experienced MD had reduced prolactin and were less likely to breastfeed. Previous literature supports the finding that depressed women tend not to breastfeed (Ystrom 2012; Dennis and McQueen 2009; Henderson et al. 2003) ; 22 out of 34 women in this study were breastfeeding (breastfeeding status of the 4 depressed women was not reported). In addition to the potential confound of breastfeeding, it is possible that prolactin determination 7 days after parturition is not representative of longitudinal alterations in the postpartum period. Parry et al. (2003) investigated serum prolactin in both pregnant women (3 with MD, 2 HCS) and postpartum women (13 with MD, 2 HCS), in the protocol described above for cortisol measurements. Prolactin was higher in depressed vs. non-depressed subjects, both in the antepartum and postpartum periods. Among the depressed women, prolactin was higher in breastfeeding vs. non-breastfeeding women. Okun et al. (2011) studied 56 pregnant, euthymic women at HR for MD were randomized to receive nortriptyline, sertraline, or placebo. Serum prolactin and self-reported sleep quality were collected biweekly in the postpartum period through 17 weeks. Prolactin levels declined in the postpartum period and stabilized at about 4 weeks postpartum. They found no association between prolactin and MD when diagnosed postpartum by DSM-IV criteria in 21.4% of the cohort.
In summary, studies focusing specifically on the association between peripartum MD and prolactin levels report discrepant findings using different study protocols. Prolactin was reduced 7 days postpartum in women who later developed MD (AbouSaleh et al. 1998) ; it was also reported to be elevated in pregnant and postpartum depressed women when measured via frequent sampling overnight (Parry et al. 2003) . A third study, with the least bias as determined by the NOS, reported no difference in prolactin in depressed vs. non-depressed women based on longitudinal sampling over 17 weeks postpartum (Okun et al. 2011 ). Sampling differences, breastfeeding status, and its associated sleep dysregulation may have contributed to discrepant findings across these reports. Deeks et al. (2003) 
Discussion
The peripartum period is characterized by a significant increase in risk for a MDE and by substantial changes in levels of hormones. This curious overlap of mood disturbances and endocrine shifts raises a critical question: are these two processes linked? To examine the extant evidence, we reviewed published literature reporting MD in the antepartum and postpartum periods in relation to cortisol, TSH, and prolactin. In healthy women, all three hormones have been shown to rise during the course of pregnancy and then fall during the postpartum period, although at different rates (Bloch et al. 2003; Parry et al. 2003) . A specific hormone would be considered to be associated with peripartum MD if the level or circadian pattern of that hormone differed significantly in healthy vs. depressed peripartum women or in women who subsequently did vs. did not develop a MDE. This review identified that timing and frequency of sampling were critically important in identifying changes in the levels of circadian-and/or sleepdependent hormones, especially during pregnancy and postpartum. Other variables that may impact the ability to detect postpartum hormonal shifts include the source of the hormonal sample and the effects of breastfeeding. Of these three hormones-cortisol, TSH, and prolactinevidence was most suggestive of a link between MD and abnormal cortisol activity, although the nature of this association is complicated by the timing and source (serum, saliva, or urine) of sample collection. In pregnant women, the most consistent finding was an association between MD and reduced cortisol in the morning, but not at other times; this was determined by both serum and salivary samples (O'Connor et al. 2014; Parry et al. 2003) . After delivery, the most consistent finding-based on salivary cortisol levels-was an association of MD with reduced morning cortisol (Taylor et al. 2009; de Rezende et al. 2016) . Seth et al. (2016) also recently concluded that maternal MD was associated with cortisol dysregulation, more specifically, by reduced morning cortisol. Among other conclusions, this review underscored the importance of repeated cortisol sampling and structured diagnostic procedures to ensure study reliability (Seth et al. 2016) , which is congruent with the findings reported here.
The observation that morning cortisol is comparatively reduced in peripartum MD may seem paradoxical, but it is possible that women with peripartum MD have a differing conveyance of cortisol signaling compared to euthymic women. While the women with MD may not experience the normal full daily range of cortisol (i.e., peak of cortisol amplitude) experienced by their healthy counterparts, it is plausible that their cortisol receptors produce an altered signal that no longer requires this brief pulsatile increase of morning cortisol. In fact, Buss and colleagues found attenuation of the CAR in healthy pregnancies as the duration of gestation progressed (Buss et al. 2009 ), and de Rezende and colleagues made the same observation in healthy, postpartum women compared to nonperipartum women (de Rezende et al. 2016) . A complete understanding of this mechanism, however, remains to be understood.
In contrast to cortisol, evidence linking abnormal levels of TSH or prolactin to peripartum MD is less compelling. It should be noted that studies reporting hypothalamicpituitary-thyroid signaling other than via TSH were not included in this review. One study using frequent, repeated sampling reported an association of MD with reduced TSH levels both during and after pregnancy, with delayed acrophase during pregnancy and advanced acrophase postpartum (Parry et al. 2003) . With regard to prolactin, only three studies were identified that assessed prolactin levels in MD in the peripartum period, and these studies yielded differing results, potentially reflecting variability introduced by differences in both sleep and breastfeeding across these studies.
This review has several limitations, including the exclusion of many articles pertaining to peripartum women with depressive symptoms and measurements of cortisol, TSH, or prolactin. However, we required a clinical diagnosis of MD to ensure objective findings, rather than subjective report. We included comparisons of the risk of bias among the studies using the Newcastle-Ottawa Quality Assessment Scale; while this scoring system is a widely used aid in the determination of study quality in systemic reviews, we acknowledge that it is an imperfect tool (Seehra et al. 2016 ). Nonetheless, it was helpful in comparing and prioritizing quality of studies.
Brockington and colleagues recently emphasized the need for more research into the causation, treatment, and prevention of mental illness during the peripartum period to prevent disruption of the mother-infant relationship and other potential negative outcomes for both mother and child (Brockington et al. 2017) . The focus of the present review was limited to cortisol, TSH, and prolactin, but many hormonal changes occur over the course of pregnancy and postpartum, and these other hormonal changes may be associated with increased (or decreased) risk for peripartum MD (Bloch et al. 2003) . For example, Moura et al. (2016) recently reviewed reports suggesting that reduced peripheral oxytocin levels in the antepartum and postpartum periods were associated with an increased risk of depressive symptoms. Although our current understanding of these many hormones in the peripartum period has not identified a predictive biomarker for MD, it is clear that maternal depression has a deleterious impact not only on the mother but also on the infant-via disturbances in the development of motor, socio-emotional, and cognitive abilities (Karam et al. 2016 ). Identifying such predictive biomarkers and the underlying hormonal mechanisms that contribute to a risk for depression in women during this critical time period should thus be a high public health priority.
